Anastrozole Tablet
Product Images NDC 42291-016

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 42291-016). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

90 (016 90)

Packaging label for ANASTROZOLE TABLETS, USP 1 mg by AvKARE. The label indicates 90 tablets in the package, with each tablet containing 1 mg of anastrozole for oral use. The label includes warnings about medication storage and keeping out of children's reach, along with manufacturer details and product codes.*

FDA Label Image

30 (016.30)

Label for ANASTROZOLE Tablets USP 1 mg by AvKARE. The label shows product name, strength of 1 mg per tablet, quantity of 30 tablets in the package, and Rx only designation. Includes storage instructions and manufacturer information from AvKARE in Pulaski, TN. Contains barcode and QR code.*

FDA Label Image

Chemical Structure (Anastrozole 01)

Chemical structure of anastrozole, showing its molecular arrangement with nitrogen-containing rings and substituted aromatic rings, consistent with the active ingredient anastrozole in the product.*

FDA Label Image

Figure 1 (Anastrozole 02)

A line graph comparing disease-free survival proportions over time in months between treatments anastrozole and tamoxifen. The vertical axis shows the proportion alive and disease-free from 0 to 1.0, while the horizontal axis shows disease-free survival in months from 0 to 90. Two lines represent randomized treatment groups: a dashed line for anastrozole and a solid line for tamoxifen. Numbers below indicate patients at risk over specified time points for both treatments.*

FDA Label Image

Figure 2 (Anastrozole 03)

A Kaplan-Meier survival curve comparing disease-free survival over months between patients treated with anastrozole and tamoxifen. The x-axis shows disease-free survival in months (0 to 90), and the y-axis shows the proportion of patients alive and disease-free (0 to 1.0). The plot includes patient counts at risk at multiple time points for both treatments.*

FDA Label Image

Figure 3 (Anastrozole 04)

A Kaplan-Meier survival curve comparing the proportion event-free over time (in months) between Anastrozole and Tamoxifen treatment groups. The x-axis represents time to event from 0 to 120 months, the y-axis shows the proportion event-free from 0.50 to 1.00. The graph includes a table below indicating patient numbers at risk at specific time points for each treatment.*

FDA Label Image

Figure 4 (Anastrozole 05)

A Kaplan-Meier survival curve comparing the proportion of event-free patients over 120 months between randomized treatments with Anastrozole and Tamoxifen. The x-axis represents time to event in months, and the y-axis shows the proportion event-free. A table below the graph lists the number of patients at risk for each treatment group at multiple time points.*

FDA Label Image

Figure 5 (Anastrozole 06)

A Kaplan-Meier survival curve chart depicting the proportion of patients not progressing over time (months) comparing randomized treatments of Anastrozole and Tamoxifen. The x-axis shows time to progression in months (0 to 42), and the y-axis shows the proportion not progressing (0 to 1). The chart includes a risk table for patient numbers at various months.*

FDA Label Image

Figure 6 (Anastrozole 07)

A line graph comparing the proportion not progressing over time in months for patients treated with Anastrozole versus Tamoxifen. The x-axis represents time to progression in months, while the y-axis shows the proportion of patients not progressing. Below the graph, numbers indicate the patients at risk at various time points for each treatment group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.